This paper is in the following e-collection/theme issue:

Non-randomized Protocols and Methods (ehealth) (542) Diabetes (154)

Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34206, first published .
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Authors of this article:

Michael Feher1 Author Orcid Image ;   William Hinton1 Author Orcid Image ;   Anna Forbes1 Author Orcid Image ;   Neil Munro2 Author Orcid Image ;   Mark Joy1 Author Orcid Image ;   David Wheeler3 Author Orcid Image ;   Simon de Lusignan1 Author Orcid Image
Article Authors Cited by Tweetations (3) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.